Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

Do Options Traders Know Something About Cassava Sciences (SAVA) Stock We Don't?

Annovis Bio

Sesen Bio Inc.

NEW YORK, NY / ACCESSWIRE / September 10, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ANVS, SESN and SAVA

AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that management will present at H.C. Wainwright's 23rd Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021.

Cassava Sciences to Present at H.C. Wainwright's 23rd Annual Global Investment Conference

Simufilam's eventual approval is still uncertain. Its fading popularity among the Reddit set is a concern as well.

Cassava Sciences Stock Still Poses Risks After Absorbing Data Controversy

Amarin Corporation Plc

Arcturus Therapeutics

Arena Pharmaceuticals

bluebird bio

Theravance Biopharma

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on InvestorPlace.

7 Busted Biotech Stocks Due for a Rebound

Radnor, Pennsylvania--(Newsfile Corp. - September 8, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Cassava securities during the Class Period may, no...

Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit

San Diego, California--(Newsfile Corp. - September 7, 2021) - Robbins Geller Rudman & Dowd LLP filed a class action lawsuit charging Cassava Sciences, Inc. (NASDAQ: SAVA) and certain of its executives with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers or acquirers of Cassava Sciences securities between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"). The Cassava Sciences class action lawsuit is pending in the...

SAVA ALERT: Robbins Geller Rudman & Dowd LLP Announces Opportunity for Cassava Sciences, Inc. Investors with Substantial Losses to Lead the Case

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 26, 2021 to file lead plaintiff applications in securities class action lawsuits against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive (the “Class Period”). These actions are pending in the United States District Co

CASSAVA SCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Cassava Sciences, Inc. - SAVA

San Francisco, California--(Newsfile Corp. - September 7, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and failed to discl

HAGENS BERMAN Reminds Cassava Sciences, Inc. (SAVA) Investors of Securities Fraud Class Action, Encourages Investors with Losses to Contact Firm's Attorneys

Boston, Massachusetts--(Newsfile Corp. - September 7, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24,...

Berman Tabacco Alerts Investors with Losses Over $200,000 of Deadline for Seeking Appointment as Lead Plaintiff in Cassava Sciences, Inc. (SAVA)

NEW YORK, Sept. 6, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

New York, New York--(Newsfile Corp. - September 5, 2021) -  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no...

Rosen, A Top Ranked Law Firm, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

James River Group Holdings

Yalla Group

NEW YORK, NY / ACCESSWIRE / September 5, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for JRVR, YALA and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

RADNOR, Pa.--(BUSINESS WIRE)---- $SAVA--Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.

Biogen

These two biotechs are going after a significant market: Alzheimer's.

Better Buy: Biogen vs. Cassava Sciences

San Francisco, California--(Newsfile Corp. - September 3, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading sta

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors with Losses to Contact Firm's Attorneys Now, Securities Fraud Class Action Pending

Boston, Massachusetts--(Newsfile Corp. - September 3, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24, 2021, inclusive. ...

SAVA DEADLINE: Berman Tabacco Alerts Investors with Losses In Excess of $200,000 of Deadline for Seeking Appointment as Lead Plaintiff in Cassava Sciences, Inc. Class Action

Cassava Sciences Inc.'s Chief Executive Remi Barbier said on Friday that recent allegations of fraud were “false and misleading” and were a result of investor interests to drive down the price of the biotechnology company's stock.

Cassava Sciences CEO says ‘enormous profit motive' behind N.Y. law firm's fraud allegations

Cassava Sciences Inc (NASDAQ: SAVA) has garnered attention recently after a citizen petition with the FDA suggested that the use of Alzheimer's candidate data is based on manipulation and misrepresentation. Related:   Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy.

Cassava CEO Goes Offensive Over Data Allegations

NEW YORK--(BUSINESS WIRE)---- $SAVA--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Western District of Texas on behalf of those who acquired Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities from September 14, 2020 through August 27, 2021, inclusive (the “Class Period”). Investors have until October 26, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Cassava is a clinical

INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors

Cassava's unchallenged safety and cognition data will result in the FDA allowing it to conduct a Phase 3 trial. SAVA stock is a buy.

Fraud Allegations Are Unlikely to Keep Cassava Stock Down

RADNOR, Pa., Sept. 3, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (NASDAQ:  SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. - SAVA

AUSTIN, Texas, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today released a public statement regarding recent allegations made against the Company.

Cassava Sciences Releases a Public Statement Regarding Recent Allegations

SAVA stock is still one of the best performers this year, but the recent allegations mean shares will fall further as the story develops. The post Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations appeared first on InvestorPlace.

Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations

Investing in biotech stocks can pay off big, but only if their research pans out. Pay attention to the risk-reward ratio -- and control your greed.

News for Cassava Sciences Inc Stock (SAVA)